Events

The poster presentation covers data from otenaproxesul’s recent pharmacokinetic/pharmacodynamic (“PK/PD”) study. It was presented at the 49th Annual Regional Anesthesia and Pain Medicine Meeting by Dr. Joseph Stauffer, Antibe’s Chief Medical Officer.

The poster presentation covers data from otenaproxesul’s recent pharmacokinetic/pharmacodynamic (“PK/PD”) study. It was presented at the 40th Annual Meeting of the American Academy of Pain Medicine by Dr. Joseph Stauffer, Antibe’s Chief Medical Officer.

Hear from liver safety expert Dr. Paul B. Watkins, a distinguished professor at the UNC Eshelman School of Pharmacy, Dr. Brett Howell, President of Quantitative Systems Pharmacology Solutions at Simulations Plus, and Dan Legault, CEO of Antibe Therapeutics.   The DILIsym® liver safety prediction platform is a quantitative systems toxicology (QST) tool used for liver … Continued

Learn about the benefits of otenaproxesul’s new formulation, dive into Antibe’s recently released data and Phase II planning, and explore the future of pain management.   As the opioid crisis drives prescribers, patients, payors and policymakers toward non-addictive alternatives, nonsteroidal anti-inflammatory drugs (NSAIDs) are increasingly employed to treat acute pain. However, today’s NSAIDs can cause … Continued

Join Dr. Joseph Stauffer, Antibe’s Chief Medical Officer, as he chairs the opening day of the USA Clinical Trials Innovation & Outsourcing Programme. The event aims to help participants learn, collaborate and contribute to the advancement of clinical trials industry.